SCHEMBL7147748

SCHEMBL7147748

CCOC(=O)c1sc(NC(=O)NCc2ccccc2)nc1C

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.69
CSNK1D P48730 3/20 0.68
RAB9A P51151 8/20 0.64
SMN1; SMN2 Q16637 8/20 0.64
MEN1 O00255 5/20 0.64
KMT2A Q03164 5/20 0.64
LCK P06239 1/20 0.64
HPGD P15428 6/20 0.63
MAPT P10636 2/20 0.63
ALDH1A1 P00352 6/20 0.62
KDM4E B2RXH2 2/20 0.62
LMNA P02545 1/20 0.61
NPSR1 Q6W5P4 1/20 0.61
POLB P06746 1/20 0.61
GSK3A P49840 1/20 0.60
GSK3B P49841 1/20 0.60
NFKB1 P19838 1/20 0.60
NFKB2 Q00653 1/20 0.60
RELA Q04206 1/20 0.60
GAA P10253 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7144868 0.87 LCK (0.70) NPC1CSNK1DRAB9ASMN1; SMN2LCK
SCHEMBL4920930 0.84 SMN1; SMN2 (0.78) NPC1CSNK1DRAB9ASMN1; SMN2MEN1
SCHEMBL3584407 0.81 SMN1; SMN2 (0.80) NPC1CSNK1DRAB9ASMN1; SMN2MEN1
SCHEMBL12443650 0.80 NPC1 (0.87) NPC1CSNK1DRAB9ASMN1; SMN2MEN1
SCHEMBL18529291 0.79 NAMPT (0.57) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL7301734 0.79 SMN1; SMN2 (0.67) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL7147053 0.79 ALDH1A1 (0.74) NPC1RAB9ASMN1; SMN2MEN1KMT2A
SCHEMBL774793 0.78 LCK (1.00) NPC1RAB9ASMN1; SMN2LCKALDH1A1
SCHEMBL2885791 0.78 MAPT (1.00) NPC1RAB9AMEN1KMT2AHPGD
SCHEMBL3591110 0.78 SCD (0.73) NPC1RAB9ASMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0928790-B1 Thiazole derivatives HOFFMANN LA ROCHE (CH) 2003-03-05 EP disclosed
EP-0928793-B1 Thiazole derivatives HOFFMANN LA ROCHE (CH) 2002-05-15 EP disclosed
US-6344562-B1 ANTITUMOR AGENTS HOFFMANN-LA ROCHE INC. 2002-02-05 US disclosed
US-20020010316-A1 Thiazole derivatives ALIG LEO (CH) 2002-01-24 US disclosed
US-6320054-B1 INHIBIT BINDING OF ADHESIVE PROTEINS TO THE SURFACE OF DIFFERENT TYPES F CELL AND ACCORDINGLY INFLUENCE CELL-CELL AND CELL-MATRIX INTERACTIONS. HOFFMAN-LA ROCHE INC. 2001-11-20 US disclosed
US-6100282-A Thiazole derivatives HOFFMAN-LA ROCHE INC. (US) 2000-08-08 US disclosed
US-6001855-A REACTING A THIAZOLE DERIVATIVE AND A CYCLIC AMINE DERIVATIVE; INHIBITS BINDING OF ADHESIVE PROTEINS TO THE SURFACE OF DIFFERENT TYPES OF CELL AND ACCORDINGLY INFLUENCE CELL-CELL AND CELL-MATRIX INTERACTIONS HOFFMAN-LA ROCHE INC. (US) 1999-12-14 US disclosed
EP-0928793-A1 Thiazole derivatives F. HOFFMANN-LA ROCHE AG (CH) 1999-07-14 EP disclosed
EP-0928790-A1 Thiazole derivatives F. HOFFMANN-LA ROCHE AG (CH) 1999-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010316-A1 Thiazole derivatives VCAM1, SOST, TGFB1 NPC1 987/4885CSNK1D 2051/4885RAB9A 1440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.